230 related articles for article (PubMed ID: 10499610)
1. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
Grem JL; McAtee N; Murphy RF; Balis FM; Cullen E; Chen AP; Hamilton JM; Steinberg SM; Quinn M; Sorensen JM; Arbuck SG; Lawrence D; Pang J; Allegra CJ
Clin Cancer Res; 1997 Jul; 3(7):1125-34. PubMed ID: 9815792
[TBL] [Abstract][Full Text] [Related]
5. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Yee LK; Allegra CJ; Steinberg SM; Grem JL
J Natl Cancer Inst; 1992 Dec; 84(23):1820-5. PubMed ID: 1433371
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
7. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
Ismail AS; Quinn MG; Wright MA; Ernst A; Kao V; Grogan L; Parr A; Grollman F; Kirsch IR; Grem JL
Oncol Rep; 2005 Jun; 13(6):1145-52. PubMed ID: 15870935
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
[TBL] [Abstract][Full Text] [Related]
9. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
10. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
Sinnige HA; Buter J; de Vries EG; Uges DR; Roenhorst HW; Verschueren RC; Sleijfer DT; Willemse PH; Mulder NH
Eur J Cancer; 1993; 29A(12):1715-20. PubMed ID: 8398300
[TBL] [Abstract][Full Text] [Related]
17. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
[TBL] [Abstract][Full Text] [Related]
18. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
[TBL] [Abstract][Full Text] [Related]
19. Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma.
Wadler S; Haynes H; Rozenblit A; Hu X; Kaleya R; Wiernik PH
Cancer J Sci Am; 1998; 4(5):331-7. PubMed ID: 9815298
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
Sporn JR; Buzaid AC; Slater D; Cohen N; Greenberg BR
Am J Clin Oncol; 1997 Feb; 20(1):81-3. PubMed ID: 9020295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
